Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac, compared with Engerix-B in healthy Asian adults: A phase 3 randomized clinical trial

CONCLUSIONS: The two 3A-HBV lots had equivalent immunogenicity, but lot B elicited faster onset of seroprotection and higher anti-HBs titers than both lot A and 1A-HBV in an Asian population. This supports 3A-HBV lot B as an effective choice for HBV vaccination, with a favorable safety profile. ClinicalTrials.gov: NCT04531098.PMID:34116873 | DOI:10.1016/j.vaccine.2021.05.067
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research